More recently, Puglia et al. set out to improve the delivery of the benefits of sesamol to the skin by developing a nanostructured lipid carrier for topical administration. They synthesized two different carrier systems and performed an in vitro percutaneous absorption study in excised human skin to determine antioxidant activity. The carrier systems differed by oil phase: One contained Miglyol 812 (nanostructured lipid carrier–M) and the other contained sesame oil (nanostructured lipid carrier–PLUS). Greater encapsulation efficiency was reported when sesame oil was employed as the oil phase, but both products displayed the capacity in vitro to control the rate of sesamol diffusion through the skin, compared with reference preparations. Both formulations also showed the extended antioxidant activity of sesamol, particularly the nanostructured lipid carrier–PLUS.3
Conclusion
Sesame seed oil has a long, storied history in several traditional medicine systems. Sesamol is a strong antioxidant present only in processed sesame oil that appears to contribute to a range of cutaneous effects. Research is promising in terms of the potential dermatologic benefits of this naturally derived compound, but much more investigation is necessary.Dr. Baumann is a private practice dermatologist, researcher, author and entrepreneur who practices in Miami. She founded the Cosmetic Dermatology Center at the University of Miami in 1997. Dr. Baumann has written two textbooks: “Cosmetic Dermatology: Principles and Practice” (New York: McGraw-Hill, 2002) and “Cosmeceuticals and Cosmetic Ingredients” (New York: McGraw-Hill, 2014). She also wrote a New York Times Best Sellers book for consumers, “The Skin Type Solution” (New York: Bantam Dell, 2006). Dr. Baumann has received funding for advisory boards and/or clinical research trials from Allergan, Evolus, Galderma, and Revance. She is the founder and CEO of Skin Type Solutions Franchise Systems LLC.
References
1. Sato Y et al. Yakugaku Zasshi. 1991 Jan;111(1):51-8.
2. Bhardwaj R et al. Anticancer Agents Med Chem. 2017;17(5):726-33.
3. Puglia C et al. Planta Med. 2017 Mar;83(5):398-404.
4. Bankole MA et al. Afr J Tradit Complement Altern Med. 2007; 4(4): 427-33.
5. Kapadia GJ et al. Pharmacol Res. 2002 Jun;45(6):499-505.
6. Ramachandran S et al. Arch Dermatol Res. 2010 Dec;302(10):733-44.
7. Sharma S and Kaur IP. Int J Dermatol. 2006 Mar;45(3):200-8.
8. Srisayam M et al. J Cosmet Sci. 2014 Mar-Apr;65(2):69-79.
9. Baek SH and Lee SH. Exp Dermatol. 2015 Oct;24(10):761-6.
10. Geetha T et al. J Drug Target. 2015 Feb;23(2):159-69.